SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges link.springer.com/article…
πŸ‘︎ 3
πŸ’¬︎
πŸ‘€︎ u/montaukwhaler
πŸ“…︎ Aug 01 2020
🚨︎ report
Comparison of PD‐L1 immunohistochemistry assays and response to PD‐1/L1 inhibitors in advanced non‐small cell lung cancer in clinical practice - Villaruz - - Histopathology onlinelibrary.wiley.com/d…
πŸ‘︎ 2
πŸ’¬︎
πŸ‘€︎ u/montaukwhaler
πŸ“…︎ Aug 18 2018
🚨︎ report
Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis sciencedirect.com/science…
πŸ‘︎ 2
πŸ’¬︎
πŸ‘€︎ u/montaukwhaler
πŸ“…︎ Jan 28 2020
🚨︎ report
FDA Clears First Cancer Drug Based on Genetics of Disease, Not Tumor Location - "new class of drugs called PD-1 or PD-L1 inhibitors that help the immune system fight cancer by blocking a mechanism tumors use to evade detection." scientificamerican.com/ar…
πŸ‘︎ 181
πŸ’¬︎
πŸ‘€︎ u/mvea
πŸ“…︎ May 24 2017
🚨︎ report

Please note that this site uses cookies to personalise content and adverts, to provide social media features, and to analyse web traffic. Click here for more information.